BMS pulls speedy Opdivo approval for liver cancer in USBristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for Share XBMS pulls speedy Opdivo approval for liver cancer in UShttps://pharmaphorum.com/news/bms-pulls-speedy-opdivo-approval-in-liver-cancer-in-us/
Keytruda beats Opdivo to first-line oesophageal cancer OK in EuropeMerck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer Share XKeytruda beats Opdivo to first-line oesophageal cancer OK in Europehttps://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/
Keytruda should lose stomach cancer indication, says ODACThe FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co’s Keytruda of its accelerated Share XKeytruda should lose stomach cancer indication, says ODAChttps://pharmaphorum.com/news/keytruda-should-lose-stomach-cancer-indication-says-odac/
Merck gets a leg-up for Keytruda in first-line kidney cancerNew phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the Share XMerck gets a leg-up for Keytruda in first-line kidney cancerhttps://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/
Heat Bio’s shares ignite on Opdivo combination data in NSCLCThe pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival Share XHeat Bio’s shares ignite on Opdivo combination data in NSCLChttps://pharmaphorum.com/news/heat-bios-shares-ignite-on-opdivo-combination-data-in-nsclc/
Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerNICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in Share XUnconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerhttps://pharmaphorum.com/news/unconvinced-by-nhs-test-run-nice-rejects-bms-opdivo-in-head-and-neck-cancer/
BMS calls time on brain cancer trial as Opdivo misses second targetBristol Myers-Squibb has put out another downbeat “update” announcement about its immunotherapy Opdivo in an aggressive form of Share XBMS calls time on brain cancer trial as Opdivo misses second targethttps://pharmaphorum.com/news/bms-calls-time-on-brain-cancer-trial-as-opdivo-misses-second-target/
FDA kicks off review of second kidney cancer combo based on BMS’ OpdivoBristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy Share XFDA kicks off review of second kidney cancer combo based on BMS’ Opdivohttps://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/
FDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomaBristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication Share XFDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomahttps://pharmaphorum.com/news/fda-approves-bms-opdivo-and-yervoy-combination-in-first-line-mesothelioma/
